Erik Wilker

2.5k total citations
24 papers, 1.5k citations indexed

About

Erik Wilker is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Erik Wilker has authored 24 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 9 papers in Oncology and 3 papers in Hematology. Recurrent topics in Erik Wilker's work include Ubiquitin and proteasome pathways (7 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Cancer-related Molecular Pathways (4 papers). Erik Wilker is often cited by papers focused on Ubiquitin and proteasome pathways (7 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Cancer-related Molecular Pathways (4 papers). Erik Wilker collaborates with scholars based in United States, Canada and Switzerland. Erik Wilker's co-authors include Michael B. Yaffe, Stephen C. Artim, Robert A. Grant, Joseph L. Kissil, Tyler Jacks, Kristen C. Johnson, Matthew S. Eckman, Yun Feng, John DiGiovanni and Stephen J. Smerdon and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Molecular Cell.

In The Last Decade

Erik Wilker

23 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erik Wilker United States 16 1.1k 270 268 138 127 24 1.5k
Katrina Diener United States 13 1.3k 1.2× 199 0.7× 237 0.9× 203 1.5× 85 0.7× 18 1.7k
Emmanuel Normant United States 22 1.3k 1.2× 417 1.5× 370 1.4× 235 1.7× 111 0.9× 50 2.0k
Lynn McGarry United Kingdom 18 992 0.9× 345 1.3× 337 1.3× 102 0.7× 70 0.6× 33 1.5k
Jörg Vervoorts Germany 19 1.3k 1.2× 198 0.7× 614 2.3× 189 1.4× 87 0.7× 26 1.9k
Bruce D. Cuevas United States 19 1.5k 1.3× 271 1.0× 430 1.6× 277 2.0× 114 0.9× 25 2.1k
Daniel T. Dransfield United States 18 780 0.7× 195 0.7× 283 1.1× 139 1.0× 68 0.5× 46 1.2k
Miguel A. Prado United States 17 1.3k 1.2× 432 1.6× 173 0.6× 127 0.9× 127 1.0× 30 1.7k
Grégoire Prévost France 24 1.0k 0.9× 110 0.4× 645 2.4× 70 0.5× 93 0.7× 56 1.7k
Richard I. Feldman United States 11 1.3k 1.2× 347 1.3× 524 2.0× 158 1.1× 66 0.5× 15 1.8k
Sally A. Prigent United Kingdom 16 775 0.7× 188 0.7× 483 1.8× 95 0.7× 30 0.2× 23 1.3k

Countries citing papers authored by Erik Wilker

Since Specialization
Citations

This map shows the geographic impact of Erik Wilker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Wilker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Wilker more than expected).

Fields of papers citing papers by Erik Wilker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Wilker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Wilker. The network helps show where Erik Wilker may publish in the future.

Co-authorship network of co-authors of Erik Wilker

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Wilker. A scholar is included among the top collaborators of Erik Wilker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Wilker. Erik Wilker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lazarides, Katherine, Yi Yu, Shangtao Liu, et al.. (2025). CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors. Molecular Cancer Therapeutics. 24(9). 1466–1479. 1 indexed citations
2.
Ericsson, Anna, David J. Richard, Erik Wilker, et al.. (2024). FT-4202, a selective pyruvate kinase R activator for sickle cell disease. Experimental Hematology. 141. 104673–104673. 1 indexed citations
3.
Caligiuri, Maureen, Erik Wilker, Lili Yao, et al.. (2023). FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer. Targeted Oncology. 18(2). 269–285. 20 indexed citations
4.
Stehn, Justine, Scott Floyd, Erik Wilker, et al.. (2023). MAPKAP Kinase-2 phosphorylation of PABPC1 controls its interaction with 14-3-3 proteins after DNA damage: A combined kinase and protein array approach. Frontiers in Molecular Biosciences. 10. 1148933–1148933.
5.
Briggs, Karen K., Erik Wilker, Charles B. Davis, et al.. (2022). 24P Evidence for synergy between TNG908, an MTAPnull-selective PRMT5 inhibitor, and sotorasib in an MTAPnull/KRASG12C xenograft model. Annals of Oncology. 33. S12–S12. 3 indexed citations
6.
Schroeder, Patricia, Keertik Fulzele, Maria Ribadeneira, et al.. (2022). Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. Journal of Pharmacology and Experimental Therapeutics. 380(3). 210–219. 28 indexed citations
7.
Briggs, Kimberly J., Kevin M. Cottrell, Erik Wilker, et al.. (2022). Abstract 3941: TNG908 is an MTAPnull-selective PRMT5 inhibitor that drives tumor regressions in MTAP-deleted xenograft models across multiple histologies. Cancer Research. 82(12_Supplement). 3941–3941. 5 indexed citations
8.
Wilker, Erik, et al.. (2010). Microfluidic Preparative Free-Flow Isoelectric Focusing: System Optimization for Protein Complex Separation. Analytical Chemistry. 82(4). 1253–1260. 1 indexed citations
9.
Yi, Chunling, Erik Wilker, Michael B. Yaffe, Anat Stemmer‐Rachamimov, & Joseph L. Kissil. (2008). Validation of the p21-Activated Kinases as Targets for Inhibition in Neurofibromatosis Type 2. Cancer Research. 68(19). 7932–7937. 55 indexed citations
10.
Wilker, Erik, Marcel A.T.M. van Vugt, Stephen C. Artim, et al.. (2007). 14-3-3σ controls mitotic translation to facilitate cytokinesis. Nature. 446(7133). 329–332. 176 indexed citations
11.
Lu, Jerry, Okkyung Rho, Erik Wilker, Linda Beltrán, & John DiGiovanni. (2007). Activation of Epidermal Akt by Diverse Mouse Skin Tumor Promoters. Molecular Cancer Research. 5(12). 1342–1352. 30 indexed citations
12.
Charest, Al, Erik Wilker, Margaret E. McLaughlin, et al.. (2006). ROS Fusion Tyrosine Kinase Activates a SH2 Domain–Containing Phosphatase-2/Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Signaling Axis to Form Glioblastoma in Mice. Cancer Research. 66(15). 7473–7481. 120 indexed citations
13.
Wilker, Erik, Robert A. Grant, Stephen C. Artim, & Michael B. Yaffe. (2005). A Structural Basis for 14-3-3σ Functional Specificity*♦. Journal of Biological Chemistry. 280(19). 18891–18898. 203 indexed citations
14.
Wilker, Erik, Jerry Lu, Okkyung Rho, et al.. (2005). Role of PI3K/Akt signaling in insulin‐like growth factor‐1 (IGF‐1) skin tumor promotion. Molecular Carcinogenesis. 44(2). 137–145. 60 indexed citations
15.
Wilker, Erik & Michael B. Yaffe. (2004). 14-3-3 Proteins—a focus on cancer and human disease. Journal of Molecular and Cellular Cardiology. 37(3). 633–642. 208 indexed citations
16.
Brown, Glenn E., Mary Q. Stewart, Sarah A. Bissonnette, et al.. (2004). Distinct Ligand-dependent Roles for p38 MAPK in Priming and Activation of the Neutrophil NADPH Oxidase. Journal of Biological Chemistry. 279(26). 27059–27068. 90 indexed citations
17.
Kissil, Joseph L., Erik Wilker, Kristen C. Johnson, et al.. (2003). Merlin, the Product of the Nf2 Tumor Suppressor Gene, Is an Inhibitor of the p21-Activated Kinase, Pak1. Molecular Cell. 12(4). 841–849. 199 indexed citations
18.
Li, Jiejin, Brandi L. Williams, L.F. Haire, et al.. (2002). Structural and Functional Versatility of the FHA Domain in DNA-Damage Signaling by the Tumor Suppressor Kinase Chk2. Molecular Cell. 9(5). 1045–1054. 180 indexed citations
19.
20.
Wilker, Erik, et al.. (1996). Characterization of Charge Change Super-repressor Mutants oftrpRepressor: Effects on Oligomerization Conformation, Ligation and Stability. Journal of Molecular Biology. 264(1). 32–45. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katrina Diener Breakdown of academic impact, for papers by Emmanuel Normant Breakdown of academic impact, for papers by Lynn McGarry Breakdown of academic impact, for papers by Jörg Vervoorts Breakdown of academic impact, for papers by Bruce D. Cuevas Breakdown of academic impact, for papers by Daniel T. Dransfield Breakdown of academic impact, for papers by Miguel A. Prado Breakdown of academic impact, for papers by Grégoire Prévost Breakdown of academic impact, for papers by Richard I. Feldman Breakdown of academic impact, for papers by Sally A. Prigent
Rankless by CCL
2026